# Renal Tubular Disorders: Pathophysiology and Clinical Management ## Learning Objectives By completion of this handout, students will be able to: 1. Understand the pathophysiology of hereditary tubulopathies affecting renal electrolyte and acid-base handling 2. Distinguish Bartter syndrome (Types I-V) from Gitelman syndrome clinically and genetically 3. Recognize and manage renal tubular acidosis (RTA Types 1, 2, and 4) 4. Diagnose Fanconi syndrome and cystinosis; initiate cysteamine therapy 5. Understand nephrogenic diabetes insipidus and differentiate congenital from acquired forms 6. Recognize Liddle syndrome and pseudohypoaldosteronism as monogenic hypertension disorders 7. Understand nephronophthisis and ciliopathies in children 8. Recognize clinical presentation patterns and guide diagnostic workup for each disorder ------------------------------------------------------------------------ ## I. BARTTER AND GITELMAN SYNDROMES ### A. Overview of Bartter and Gitelman Syndromes **Classification:** Autosomal recessive salt-wasting tubulopathies characterized by: - **Hypokaliemia** (low serum potassium) - **Metabolic alkalosis** - **Hyperreninemia and hyperaldosteronemia** (secondary to volume depletion) - **NORMAL blood pressure** (distinguishes from pseudohyperaldosteronism) - **Normal renal function** (GFR preserved early; may decline with age) **Historical Context:** - Bartter syndrome first described 1962; Gitelman 1966 - Originally called “normotensive hyperreninemic hypokalemic alkalosis” - Genetic characterization began 1990s with identification of mutations in genes encoding ion transporters and signaling molecules ### B. Bartter Syndrome Types I-V **Genetic Basis and Pathophysiology:** | Type | Gene | Protein | Location | Mechanism | |----|----|----|----|----| | **I** | SLC12A1 | Na-K-2Cl cotransporter (NKCC2) | TAL thick ascending limb | ↓ NaCl reabsorption | | **II** | KCNJ1 | ROMK potassium channel | TAL, distal collecting duct | ↓ K+ recycling in TAL; ↓ positive potential | | **III** | CLCNKB | ClC-Kb chloride channel | TAL, DCT | ↓ Cl⁻ reabsorption | | **IV** | CASR | Calcium-sensing receptor | TAL | ↓ Mg²⁺ reabsorption; secondary effects | | **V** | CASR (gain of function) | Calcium-sensing receptor | TAL | Mimics hypercalcemia; ↓ PTH | **Pathophysiology (All Types):** 1. Defect in salt reabsorption in thick ascending limb (TAL) of loop of Henle 2. → Volume depletion → activation of renin-angiotensin-aldosterone system (RAAS) 3. → Increased sodium reabsorption in distal tubule via epithelial sodium channel (ENaC) 4. → Increased potassium and hydrogen ion secretion in collecting duct 5. → Hypokalemia and metabolic alkalosis 6. → Renal vasoconstriction from angiotensin II (GFR relatively preserved) **Clinical Presentation:** **Prenatal/Neonatal (Type I and II particularly):** - Polyhydramnios (increased fetal urine output) - Preterm delivery (50% of cases) - Neonatal presentation: Lethargy, poor feeding, muscle weakness, seizures (severe hypokalemia) **Infancy/Early Childhood (Type III typically presents here):** - Failure to thrive - Polyuria, polydipsia (impaired concentrating ability; acquired nephrogenic diabetes insipidus) - Recurrent episodes of hypokalemia with muscle weakness, cramps, tetany - Developmental delay if untreated - Craving for salt (salt-wasting state) **Childhood/Adolescence:** - Growth failure - Musculoskeletal manifestations: Muscle weakness, fatigue, cramping - Developmental impairment if inadequately treated - Progressive renal insufficiency (Types I-III more likely; incidence increases with age) - Nephrolithiasis risk (alkalosis, hypercalciuria in Types I and II) - Hearing loss (Type IV particularly; associated with mutations affecting chloride channel expression in cochlea) **Type I-Specific Features:** - **Most severe in utero presentation** (polyhydramnios, preterm birth common) - Neonatal onset with severe symptoms - Nephrogenic diabetes insipidus (difficulty concentrating urine) - Hypercalciuria and nephrolithiasis risk **Type II-Specific Features:** - Neonatal presentation - ROMK channel mutations → severe hyperkalemia possible early (unlike other types) - Rapid progression to severe symptoms **Type III-Specific Features:** - Later childhood onset (often age 2-6 years) - Milder symptoms early; progressive - Hearing loss not associated - Somewhat slower progression than Types I-II **Type IV-Specific Features:** - CASR mutations → associated hypercalcemia - **Hearing loss (sensorineural, progressive)** - Polyuria from hypercalcemia - May present with seizures from hypokalemia **Type V-Specific Features:** - Gain-of-function CASR mutation - Mimics primary hyperparathyroidism picture - Hypercalcemia, hypercalciuria - Suppressed PTH level (distinguishes from hyperparathyroidism) **Laboratory Findings (All Types):** | Finding | Value | |----|----| | **Serum potassium** | \<3.5 mEq/L (often \<3.0) | | **Serum chloride** | \<98 mEq/L | | **Serum HCO₃⁻** | \>28 mEq/L | | **Blood pH** | \>7.45 (alkalemia) | | **Serum renin** | Elevated (5-10× normal) | | **Plasma aldosterone** | Elevated (\>15 ng/dL) | | **Serum sodium** | Low-normal to normal | | **Serum magnesium** | Low (especially Type III) | | **Urinary potassium** | Elevated | | **Urinary chloride** | Elevated | | **Blood pressure** | Normal (distinguishes from pseudohypoaldosteronism) | | **Serum creatinine** | Normal early; may rise with age | **Diagnostic Approach:** 1. Confirm hypokalemic metabolic alkalosis with normal BP 2. Assess renin-aldosterone axis (elevated = consistent with diagnosis) 3. Genetic testing: NKCC2, ROMK, ClC-Kb, CASR gene sequencing 4. Exclude other causes: vomiting, diuretic abuse, hyperaldosteronism 5. **Prenatal diagnosis possible** with early genetic testing (very early onset polyhydramnios suspicious) **Management:** **Potassium Replacement:** - **Dose:** 1-4 mEq/kg/day (in divided doses; see target below) - **Target serum K+:** 3.5-4.5 mEq/L (higher goals—closer to 4.5—reduce hypokalemia-related symptoms) - **Forms:** Potassium chloride (preferred, replaces both K+ and Cl⁻), potassium acetate - **Monitoring:** Check serum K+ every 2-4 weeks initially; then every 1-3 months once stable **NSAIDs:** - **Mechanism:** Inhibit prostaglandin synthesis → reduce renal renin release → reduce secondary aldosteronism → reduce K+ wasting - **Drugs:** Indomethacin (first-line), ibuprofen, naproxen - **Dosing:** Indomethacin 0.5-1.0 mg/kg/day (divided, max 75 mg/day) - **Efficacy:** Raises serum K+ by 0.5-1.5 mEq/L in majority of patients - **Monitoring:** Monitor renal function, GFR; risk of chronic kidney disease with long-term NSAID use - **Relative contraindications:** Renal insufficiency, GI bleeding, platelet dysfunction - **Duration:** Often lifelong therapy needed; some reduction possible with maturity/improved dietary compliance **ACE Inhibitors/Angiotensin Receptor Blockers:** - **Mechanism:** Reduce angiotensin II generation/signaling → reduce aldosterone secretion - **Less effective alone than NSAIDs** but additive when combined - **Use:** Particularly if NSAID contraindicated or insufficient response - **Caution:** May cause hyperkalemia if renal function declines (monitor K+) **Salt Supplementation:** - **Rationale:** Restore intravascular volume; reduce RAAS activation - **Approach:** Encourage dietary salt intake; may need oral salt supplementation - **Risk:** Must balance against hypertension risk if renal function declines with age **Dietary Management:** - **High sodium diet** (3-4 g sodium/day) - **Adequate fluid intake** (address polyuria) - **Nutritional support** (growth failure prevention) - **Calcium intake:** Assess for nephrolithiasis risk; evaluate urinary calcium **Specific Management by Type:** - **Types I-II (severe):** More aggressive K+ replacement, NSAIDs, may need ACE inhibitor added - **Type III:** Often lower initial severity; respond better to NSAIDs alone; slower progression - **Type IV:** Management of hypercalcemia (thiazide diuretics, adequate hydration) **Long-Term Complications:** - Progressive renal insufficiency (30-40% reach ESRD by adulthood in Types I-II; less common in Type III) - Nephrolithiasis - Growth failure if inadequately treated - Hearing loss (Type IV) - Hypertension develops in some patients with aging (paradoxical; mechanism unclear) **Outcome:** - Early diagnosis and aggressive replacement therapy improves growth and development - Neurodevelopmental outcome excellent if treated before age 2-3 years - Many patients achieve normal adult height with adequate therapy - Prognosis for renal function variable; progression to ESRD possible but not inevitable ------------------------------------------------------------------------ ### C. Gitelman Syndrome **Genetics:** - Gene: SLC12A3 (chromosome 16q13) - Protein: Thiazide-sensitive sodium-chloride cotransporter (NCCT) in distal convoluted tubule (DCT) - Inheritance: Autosomal recessive - Incidence: 1 in 40,000 live births (more common in some populations: Japan, Turkey) **Pathophysiology:** 1. Defect in NCCT → impaired NaCl reabsorption in DCT 2. → Volume depletion → RAAS activation 3. → Increased K+ and H+ secretion in collecting duct (via aldosterone effect) 4. → **Hypokalemia + metabolic alkalosis** 5. Unique feature: **Hypocalciuria** (increased urinary magnesium, decreased urinary calcium) **Clinical Presentation:** **Age of Onset:** - Usually **age 6-16 years** (later than Bartter; varies widely) - Some present in infancy; others not until adulthood **Symptoms:** - Muscle weakness, cramps, tetany (from hypokalemia) - Paresthesias - Polydipsia, polyuria (from hypokalemia-induced nephrogenic DI) - Growth retardation (if untreated) - Fatigue, decreased exercise tolerance - Periodic paralysis (rare; severe hypokalemia) **Clinical Features (Distinguishes from Bartter):** - **Hypomagnesemia** (more severe and clinically significant than Bartter) - **Hypocalciuria** (low urinary calcium; distinguishes from Bartter types with hypercalciuria) - **Normal to low serum calcium** (hypokalemia-induced, mild) - **Chondrocalcinosis** (calcium pyrophosphate deposition in joints; occurs from hypomagnesemia) - **Absence of hearing loss** (unlike Bartter Type IV) **Laboratory Findings:** | Finding | Value | |------------------------|----------------------------------------------------| | **Serum potassium** | \<3.5 mEq/L | | **Serum magnesium** | \<1.7 mg/dL (often \<1.5) | | **Serum calcium** | Normal to low | | **Serum chloride** | \<98 mEq/L | | **Serum HCO₃⁻** | \>28 mEq/L | | **Plasma renin** | Elevated | | **Plasma aldosterone** | Elevated | | **Urinary calcium** | **LOW** (\<100 mg/day; distinguishes from Bartter) | | **Urinary magnesium** | Elevated | | **Blood pressure** | Normal | **Diagnostic Approach:** 1. Confirm hypokalemic metabolic alkalosis with normal BP 2. Check serum magnesium (expect marked hypomagnesemia in Gitelman) 3. Check urinary calcium (low in Gitelman; normal-high in Bartter) 4. Genetic testing: SLC12A3 gene sequencing 5. Exclude secondary causes (diuretic abuse, vomiting) **Management:** **Potassium Replacement:** - Similar to Bartter; however, **repletion often difficult** due to magnesium depletion limiting K+ correction - **Goal:** Serum K+ 3.5-4.5 mEq/L - Forms: Potassium chloride (combined with magnesium replacement often necessary) **Magnesium Replacement:** - **Critical difference from Bartter:** Magnesium depletion severe and must be corrected for K+ repletion to be effective - **Oral replacement:** Magnesium oxide, magnesium gluconate - **Dose:** 0.3-0.6 g elemental Mg daily (divided doses; often 2-4 g MgO daily) - **Target serum Mg²⁺:** \>1.7 mg/dL (ideally \>2.0) - **GI side effect:** Diarrhea common (may limit dose); switch formulations if needed - **Monitoring:** Serum Mg²⁺ every 4-8 weeks initially; monthly once stable - **Duration:** Lifelong supplementation typically required **NSAIDs:** - Similar rationale and dosing as Bartter - **Caution:** NSAIDs may cause GI symptoms; magnesium-containing NSAIDs (magnesium salicylate) may provide additional benefit - Less dramatically effective in Gitelman than Bartter; often used adjunctively **Potassium-Sparing Diuretics:** - **Amiloride:** 0.3-0.6 mg/kg/day - **Mechanism:** Blocks ENaC in collecting duct; reduces K+ and H+ secretion - **Efficacy:** May be very effective in Gitelman (better than Bartter response) - **Caution:** Risk of hyperkalemia; must monitor serum K+ - **Role:** Alternative or additive to NSAIDs if response inadequate **Thiazide Diuretics (Paradoxically):** - **Hydrochlorothiazide** at very low doses - **Rationale:** TSHould worsen hypokalemia but paradoxically, in Gitelman, may improve symptoms - Proposed mechanism: Increases urinary sodium losses → improved volume depletion compensation - **Use:** Reserved for severe refractory cases; not first-line **Dietary:** - **High sodium diet** (similar to Bartter; 3-4 g daily) - **Adequate magnesium intake** (difficult to achieve orally; supplementation necessary) - **Adequate fluid intake** (address polyuria) **Long-Term Outcome:** - **Much better prognosis than Bartter** (renal function typically preserved throughout life) - **Most patients achieve normal adult height and normal development** with adequate therapy - **ESRD very rare** in Gitelman (unlike Bartter with higher progression rate) - **Complications:** Chondrocalcinosis (calcium pyrophosphate deposition) common but often asymptomatic - Early diagnosis and treatment crucial for normal growth and development ------------------------------------------------------------------------ ## II. RENAL TUBULAR ACIDOSIS (RTA) ### A. Overview of RTA **Definition:** Metabolic acidosis resulting from dysfunction of renal tubular acid secretion or bicarbonate reabsorption, **WITHOUT significant reduction in GFR**. **Types:** - **Type 1 (Distal) RTA:** Impaired acid secretion in collecting duct - **Type 2 (Proximal) RTA:** Impaired HCO₃⁻ reabsorption in proximal tubule - **Type 4 (Hyperkalemic) RTA:** Aldosterone deficiency or resistance in collecting duct **Note:** Type 3 RTA (rare mixed proximal + distal) rarely seen in clinical practice ### B. Type 1 (Distal) RTA **Genetics and Etiology:** **Primary (Hereditary):** - **Autosomal recessive:** Gene SLC4A1 (band 3 anion exchanger; basolateral membrane) or ATP6V0B (vacuolar H+-ATPase) - **Autosomal dominant:** Gene SLC4A1 (missense mutations) - Incidence: Rare; 1 in 10,000 children (variable by ethnicity) **Secondary (More common):** - Amphotericin B - NSAIDs (chronic use) - Systemic lupus erythematosus - Sjogren syndrome - Chronic pyelonephritis - Medullary sponge kidney - Kidney transplant rejection **Pathophysiology:** - **Distal collecting duct** cannot secrete H+ ions adequately - Result: **Inability to lower urine pH** below 5.5 (normal: \<4.5) - → **Hyperchloremic metabolic acidosis** (normal anion gap) - → Increased urinary potassium and sodium losses (to maintain electroneutrality; Cl⁻ is reabsorbed instead) - → Hypokalemia (often severe) - → Hypocitraturia (citrate required for acid buffering; wasted in urine) - → Hypercalciuria (acidosis mobilizes bone calcium; reduced citrate promotes urinary calcium precipitation) **Clinical Presentation:** **Infancy/Early Childhood:** - Failure to thrive - Recurrent vomiting - Polyuria, polydipsia - Muscle weakness (from hypokalemia) - Developmental delay if untreated - Bone pain (osteomalacia from chronic acidosis) **Childhood/Adolescence:** - Growth failure - Bone disease (rickets) - Recurrent nephrolithiasis (calcium phosphate stones despite low urine pH) - Chronic diarrhea (from loss of bicarbonate) **Laboratory Findings:** | Finding | Value | |-----------------------|-------------------------------------| | **Serum HCO₃⁻** | \<15 mEq/L (may be 10-20) | | **Serum pH** | \<7.35 (acidemia) | | **Anion gap** | Normal (\<12 mEq/L) | | **Serum potassium** | Often \<3.5 mEq/L (hypokalemia) | | **Serum chloride** | High (98-110 mEq/L; hyperchloremia) | | **Urine pH** | \>5.5 (inability to acidify) | | **Urinary potassium** | Elevated | | **Urinary calcium** | Elevated (hypercalciuria) | | **Urinary citrate** | Low | | **GFR** | Normal | **Diagnostic Confirmation:** 1. **Fludrocortisone stimulation test:** Acute acid load (ammonium chloride 0.1 g/kg) → normal kidneys lower urine pH to \<5.5; RTA Type 1 cannot 2. **OR:** Furosemide + fludrocortisone test (alternative) **Management:** **Alkali Replacement:** - **Goal:** Normalize serum HCO₃⁻ (\>20 mEq/L); achieve urine pH \<5.5 if possible - **Agents:** Sodium bicarbonate, potassium citrate (preferred; replaces both HCO₃⁻ and K+) - **Dose:** 1-3 mEq/kg/day (divided in 2-4 doses) - **Target:** Serum HCO₃⁻ 20-24 mEq/L - **Titration:** Adjust based on serum HCO₃⁻ checks every 4-8 weeks **Potassium Supplementation:** - Often necessary despite bicarbonate therapy - Potassium citrate preferred (addresses both K+ and HCO₃⁻ deficiency) - Avoid potassium chloride (increases Cl⁻ load, worsening metabolic acidosis) **Prevention of Nephrolithiasis:** - Aggressive alkali therapy (maintains higher urine pH, reducing calcium phosphate precipitation) - **Thiazide diuretics:** Hydrochlorothiazide 0.5-1 mg/kg/day (reduces urinary calcium excretion) - **Citrate supplementation:** Potassium citrate (increases urinary citrate, inhibitor of stone formation) - Adequate hydration **Bone Management:** - Vitamin D supplementation (1,25-dihydroxyvitamin D3, calcitriol, 0.02-0.08 mcg/kg/day) - Calcium supplementation if deficient - Address acidosis (improves bone metabolism) **Long-Term Outcome:** - With adequate alkali and K+ replacement, growth and development normal - Adult height usually normal with early diagnosis and therapy - **Renal function preserved** (GFR normal throughout life unless nephrolithiasis causes obstruction) - **Hearing loss possible** with mutations in vacuolar H+-ATPase genes (genetic hearing loss syndromic association) ------------------------------------------------------------------------ ### C. Type 2 (Proximal) RTA **Genetics:** - Autosomal recessive: Gene SLC4A4 (sodium-bicarbonate cotransporter in proximal tubule) - Rare in isolation; often part of syndromic presentation (Fanconi syndrome) **Pathophysiology:** - **Proximal tubule** cannot reabsorb filtered HCO₃⁻ adequately - Result: **Bicarbonate wasting in urine** - Serum HCO₃⁻ drops until levels low enough to be filtered below reabsorption capacity - → **“Equilibrium point”** reached (serum HCO₃⁻ usually 15-18 mEq/L) - → Urine pH appropriately low (\<5.5); kidneys can acidify normally (distinguishes from Type 1) **Clinical Presentation:** - Similar to Type 1: growth failure, bone disease, weakness - Often associated with **Fanconi syndrome** (additional proximal tubular dysfunction: phosphate, glucose, amino acid, urate wasting) **Laboratory Findings:** | Finding | Value | |---------------------|-------------------------------------------------------| | **Serum HCO₃⁻** | 15-20 mEq/L (less severe than Type 1) | | **Anion gap** | Normal | | **Urine pH** | \<5.5 (normal acidification) | | **Urine HCO₃⁻** | Elevated | | **Serum potassium** | Variable (hypokalemia possible but often less severe) | | **GFR** | Normal to mildly reduced | **Diagnostic Distinction from Type 1:** - **Type 1:** Cannot lower urine pH (\<5.5 normal); hyperchloremia + hypokalemia prominent - **Type 2:** CAN lower urine pH (\<5.5 normally); serum HCO₃⁻ less dramatically low **Management:** - Alkali replacement: sodium bicarbonate or potassium citrate (similar doses as Type 1) - Large doses often required (may need 5-10 mEq/kg/day) due to continued wasting - Thiazide diuretics: Paradoxically effective in Type 2 (reduce glomerular filtration → reduce HCO₃⁻ wasting) - If associated with Fanconi syndrome: additional management required (see Fanconi/Cystinosis section) ------------------------------------------------------------------------ ### D. Type 4 (Hyperkalemic) RTA **Classification:** **Type 4A: Hyporenin-Hypoaldosteronism (HHA)** - Genetics: Gene mutations in renin, angiotensinogen, or aldosterone synthase - Pathophysiology: Reduced renin-aldosterone response to acid/K+ load - Etiology: Congenital (rare); acquired (diabetes, chronic kidney disease, NSAIDs, ACE inhibitors/ARBs) **Type 4B: Aldosterone Resistance (Pseudohypoaldosteronism)** - Genetics: Gene ENaC (epithelial sodium channel); autosomal recessive - Pathophysiology: Receptor or post-receptor defect in collecting duct response to aldosterone - Clinical: Salt-wasting, hyperkalemia, metabolic acidosis despite normal/high aldosterone levels **Pathophysiology (Both Types):** - **Impaired potassium secretion in collecting duct** (due to aldosterone deficiency or resistance) - → **Hyperkalemia** (serum K+ \>5.5 mEq/L) - → Reduced ammoniagenesis (K+ accumulation suppresses ammonia production) - → **Metabolic acidosis** (reduced renal acid excretion) **Clinical Presentation:** - **Hyperkalemia** (primary finding) - Metabolic acidosis (mild-to-moderate) - Cardiac arrhythmias (from hyperkalemia) - Type 4B (pseudohypoaldosteronism): **Salt-wasting, hyperkalemia, hypokalemic features** (muscle weakness despite high K+ due to transcellular shift) - Growth failure if untreated **Laboratory Findings:** | Finding | Value | |---------------------|--------------------------------------| | **Serum potassium** | \>5.5 mEq/L | | **Serum HCO₃⁻** | 15-22 mEq/L | | **Serum pH** | \<7.35 | | **Anion gap** | Normal | | **Urine pH** | Usually \>5.5 (cannot fully acidify) | **Type 4A-Specific:** - Plasma renin: Low (differentiates from Type 4B) - Aldosterone: Low **Type 4B-Specific:** - Plasma renin: Elevated (high K+ should stimulate) - Aldosterone: Elevated (resistance to hormone effect) **Management:** **Type 4A (Hypoaldosteronism):** - **Fludrocortisone:** 0.05-0.2 mg daily (synthetic aldosterone; expands volume, increases K+ excretion) - **Sodium supplementation:** Enhance volume expansion effect - **Diuretics:** Furosemide (promotes K+ wasting; careful with volume status) - Avoid NSAIDs, ACE inhibitors/ARBs (reduce aldosterone) **Type 4B (Aldosterone Resistance):** - **Fludrocortisone:** Often **ineffective** (resistance to aldosterone) - **Diuretics:** Loop and thiazide diuretics (promote K+ wasting independent of aldosterone) - **Dietary potassium restriction:** \<2 g/day - **Potassium binders:** Sodium polystyrene sulfonate, patiromer (newer agent), sodium zirconium cyclosilicate - **Alkali:** Sodium bicarbonate or potassium citrate (carefully; K+ content) **Long-Term Management:** - Regular monitoring of serum K+ and HCO₃⁻ - Dietary compliance (sodium/potassium balance) - EKG if K+ persistently \>6.5 mEq/L (assess for arrhythmia risk) ------------------------------------------------------------------------ ## III. FANCONI SYNDROME AND CYSTINOSIS ### A. Fanconi Syndrome **Definition:** Generalized dysfunction of renal proximal tubule characterized by **wasting of multiple solutes:** - Phosphate - Glucose - Amino acids - Urate - Carnitine - Bicarbonate (Type 2 RTA features) **Etiology:** **Primary (Idiopathic):** - Rare; genetic basis incompletely characterized **Secondary (More common):** - **Cystinosis** (most common genetic cause) - Tyrosinemia Type 1 - Lowe syndrome (oculocerebrorenal) - Wilson disease - Mitochondrial diseases - Dent disease - Heavy metals (mercury, lead, cadmium) - Drugs: Aminoglycosides, amphotericin B, ifosfamide, tenofovir, adefovir **Pathophysiology:** - Mitochondrial dysfunction; impaired cellular energy production - Loss of intact proximal tubule cells (epithelial cell damage) - Impaired active reabsorption mechanisms for small solutes and proteins **Clinical Presentation:** **Infantile Onset (Cystinosis):** - Failure to thrive (first year of life) - Recurrent vomiting, anorexia - Polyuria, polydipsia - Rickets (phosphate wasting → hypophosphatemia) - Photophobia, eye pain (cystine crystal accumulation in cornea) - Growth failure **Delayed Presentations (Other etiologies):** - Variable age of onset - Growth failure - Bone disease (rickets) - Renal insufficiency (progressive in some types) **Laboratory Findings:** | Solute | Finding | |--------------------|--------------------------------------------------------| | **Glucose** | Glycosuria (glucose \<400 mg/dL) | | **Amino acids** | Aminoaciduria (generalized, low/high-molecular-weight) | | **Phosphate** | Hypophosphatemia; increased urinary phosphate | | **Urate** | Hypouricemia; increased urinary urate | | **Carnitine** | Low serum carnitine | | **Bicarbonate** | Often HCO₃⁻ wasting (Type 2 RTA features) | | **Protein** | Low-molecular-weight proteinuria | | **Potassium** | Hypokalemia | | **Renal function** | Normal initially; may decline with progression | ------------------------------------------------------------------------ ### B. Cystinosis **Genetics:** - Gene: CTNS (cystine transporter 1; chromosome 17p13) - Inheritance: Autosomal recessive - Incidence: 1 in 100,000-200,000 live births **Pathophysiology:** - **Defect in cystine efflux transporter** in lysosomal membrane - → **Cystine accumulation in lysosomes** (cystine cannot exit; accumulates in crystals) - → Cellular toxicity; apoptosis of renal tubular cells - → Proximal tubule dysfunction (Fanconi syndrome) - → Progressive accumulation in other organs (eye, bone, thyroid, pancreas, CNS) **Clinical Presentation:** **Infantile-Onset Nephropathic Cystinosis (Most common, 95% of cases):** *Infancy (0-1 year):* - Presentation age 3-6 months typically - Failure to thrive, poor growth - Polyuria (2-4 liters/day; up to 10 in severe cases) - Recurrent vomiting, anorexia - Severe dehydration risk (large urinary losses) - Rickets (develops within first year) *Early Childhood (1-5 years):* - Growth failure becomes apparent (significant growth deficit if untreated) - Photophobia and eye pain (cystine crystalline deposits in cornea; “cystine crystals”) - Ocular findings: Crystal deposits in cornea (anterior and posterior surface), conjunctiva, retina; can lead to reduced visual acuity - Fanconi syndrome fully apparent: phosphate wasting, aminoaciduria, glycosuria *Progression to ESRD:* - Progressive renal insufficiency; most reach ESRD by age 10 years if untreated - **With cysteamine therapy:** ESRD delayed to age 20-30s (dramatic improvement in prognosis) - Without therapy: Renal failure by age 6-10 years **Ocular Manifestations (Distinctive):** - Photophobia, eye pain (due to crystalline deposits) - Corneal crystals (bilateral, anterior and posterior) - Visual impairment (progressive) - Retinal crystals (uncommon but possible) - **Cystine crystal deposition in eye is PATHOGNOMONIC** for cystinosis **Other Organ Involvement (Late manifestations without treatment):** - Pancreatic insufficiency (diabetes mellitus; pancreatic enzyme deficiency) - Thyroid dysfunction (hypothyroidism) - Neurodegeneration (tremor, myopathy, CNS involvement) without therapy - Bone disease (rickets from phosphate wasting, vitamin D deficiency) **Adolescent/Adult-Onset Cystinosis (Rare, \<5% of cases):** - Slower progression - May not reach ESRD until adulthood or remain stable - Ocular symptoms may be mild **Laboratory Findings:** - **Elevated urinary cystine** (hallmark finding; \>300 mg/day normal \<100) - **Elevated leukocyte cystine content** (diagnostic; \>2 nmol half-cystine per mg protein normal \<0.2) - Fanconi syndrome features: Glycosuria, amino aciduria, hypophosphatemia, hyperparathyroidism - Progressive renal insufficiency (serum creatinine rises; GFR declines) - Elevated PTH, FGF23 **Diagnosis:** 1. Clinical suspicion: Fanconi syndrome + photophobia + ocular crystals (pathognomonic) 2. Elevated 24-hour urinary cystine (\>300 mg/day) 3. **Leukocyte cystine content** (definitive; \>2 nmol/mg protein diagnostic) 4. Genetic testing: CTNS gene sequencing (confirms; allows for family counseling) 5. Slit-lamp examination: Shows crystalline deposits in cornea/conjunctiva **Management:** **Cysteamine Therapy (Cystine-Depleting Agent):** - **Mechanism:** Converts cystine to cysteine (plus cysteine-cysteamine disulfide) via mixed disulfide formation; products can exit lysosome - **Drug:** Cysteamine hydrochloride (Cystagon) or cysteamine bitartrate (Procysbi, delayed-release) - **Dosing:** - **Standard cysteamine:** 1.3 g/m²/day (divided into 4 doses every 6 hours; OR can divide into 2 doses of delayed-release) - **Delayed-release (Procysbi):** 0.65 g/m²/dose twice daily (more convenient; lower GI side effect profile) - **Target:** Leukocyte cystine content \<1 nmol/mg protein (goal is \<0.5) - **Dosing adjustment:** May require 1.3-1.9 g/m²/day depending on response **Efficacy:** - **Renal function:** Delays progression to ESRD by 10+ years; some patients never reach ESRD with early therapy - **Growth:** Normalizes with adequate cysteamine (if started \150 mEq/L) - High osmolality (\>300 mOsm/kg) - Polyuria (large output despite dehydration) - Failure to pass meconium (some cases; severe dehydration) - Fever, lethargy, seizures (from severe hypernatremia) - Diagnosis may be made emergently in NICU for hypernatremia **Infancy/Early Childhood:** - Persistent polyuria (5-15 liters/day in untreated cases) - Severe polydipsia (if access to water; comatose if denied water) - Growth failure - Developmental delay (if recurrent hypernatremic episodes) - Nephrogenic polyuria refractory to desmopressin (DDAVP) **Later Childhood:** - Chronic thirst; large fluid intake required - Massive polyuria (unresponsive to desmopressin) - Growth can be normal if water access adequate - Behavioral/emotional impact (frequent urination, bed-wetting) **Laboratory Findings:** | Finding | Value | |----|----| | **Serum sodium** | \>145 mEq/L (hypernatremia; often severe) | | **Serum osmolality** | \>300 mOsm/kg | | **Urine output** | 5-15 liters/day (polyuria) | | **Urine osmolality** | \<300 mOsm/kg (dilute; inability to concentrate) | | **Urine specific gravity** | \<1.005 (very dilute) | | **ADH (vasopressin)** | Elevated (appropriate for osmolality; fails to produce renal response) | | **Renal function** | Normal GFR initially | | **Serum potassium** | Variable; may be elevated with dehydration | **Diagnostic Confirmation:** 1. **Desmopressin (DDAVP) trial:** - Central DI responds with ↓ polyuria, ↑ urine osmolality - NDI shows **no response** to desmopressin (hallmark finding) 2. Genetic testing: AVPR2 or AQP2 gene sequencing **Management:** **Hydration:** - **Free access to water at all times** (critical; risk of severe dehydration/hypernatremia if access restricted) - Large, frequent water intake required (5-15 liters/day) - In infants: Breast/bottle feeding with water offered frequently between feeds - Education: Family must understand critical importance of unlimited water access **Thiazide Diuretics:** - **Hydrochlorothiazide:** 1-2 mg/kg/day (divided) - **Mechanism:** Produces mild volume depletion → increased proximal tubule sodium + water reabsorption → ↓ urine output to collecting duct - **Efficacy:** Reduces polyuria by 30-50% (additive with NSAIDs) - **Monitor:** Electrolytes, renal function, volume status **NSAIDs:** - **Indomethacin:** 0.5-1 mg/kg/day - **Mechanism:** Inhibits prostaglandin synthesis; reduces cAMP in collecting duct; ?direct effect on aquaporins - **Efficacy:** Modest reduction in polyuria (20-30%) - **Caution:** Monitor renal function; risk of chronic kidney disease with long-term use **Amiloride (Potassium-Sparing Diuretic):** - **Dose:** 0.3-0.6 mg/kg/day - **Mechanism:** Blocks ENaC in collecting duct; reduces intracellular Na+, enhancing aquaporin-2 expression - **Particularly useful if X-linked NDI** (may be more effective than other agents) - **Monitor:** Serum potassium (risk of hyperkalemia) **Combined Therapy:** - Often more effective: Thiazide + NSAID + amiloride - Goal: Reduce polyuria to 3-5 liters/day (more manageable) **Renal Complications:** - **Medullary nephrolithiasis** (calcium phosphate stones from chronic dehydration) - **Hydronephrosis** (from recurrent dehydration episodes) - **Chronic kidney disease** (from repeated osmotic injury; progressive in some cases) **Long-Term Outcome:** - Life-threatening complications if water access restricted - Normal growth possible with adequate management - Neurodevelopmental outcome depends on frequency/severity of hypernatremic episodes - Renal function usually preserved but at risk for late CKD - Social impact: Frequent urination, school disruption, psychological burden ------------------------------------------------------------------------ ### C. Acquired Nephrogenic Diabetes Insipidus **Common Causes:** | Category | Examples | |----|----| | **Medications** | Lithium (common), amphotericin B, cisplatin, demeclocycline, NSAIDs | | **Metabolic** | Hypercalcemia, hypokalemia | | **Renal disease** | Chronic pyelonephritis, medullary sponge kidney, polycystic kidney disease | | **Systemic** | Sickle cell, amyloidosis, sarcodosis | **Management:** - Address underlying cause (discontinue offending drug if possible) - Hydration, thiazide + NSAID therapy - More responsive to desmopressin than congenital NDI (partial response common) ------------------------------------------------------------------------ ## V. LIDDLE SYNDROME **Genetics:** - Gene: SCNN1B or SCNN1G (epithelial sodium channel, ENaC, beta or gamma subunit) - Inheritance: Autosomal dominant - Mutations: Gain-of-function (increased channel activity or stability) **Pathophysiology:** - **Overactive ENaC in collecting duct** → enhanced sodium reabsorption - → Increased potassium secretion (electroneutrality) - → **Severe hypokalemia** - → Increased hydrogen ion secretion - → **Metabolic alkalosis** - → Sodium retention → **hypertension** - Suppressed renin and aldosterone (due to volume expansion) **Clinical Presentation:** - **Early-onset hypertension** (childhood or adolescence; sometimes neonatal hypertension) - **Severe hypokalemia** (serum K+ 2.5-3.5 mEq/L) - **Metabolic alkalosis** - Muscle weakness, cramps, tetany (from hypokalemia) - Normal renal function **Laboratory Findings:** | Finding | Value | |----|----| | **Blood pressure** | Elevated (\>95th percentile for age/height) | | **Serum potassium** | \<3.5 mEq/L (often \<3.0) | | **Serum sodium** | High-normal to high | | **Serum chloride** | Low | | **Serum HCO₃⁻** | \>28 mEq/L (alkalosis) | | **Plasma renin** | LOW\ (also low in primary aldosteronism; use aldosterone to distinguish) | | **Aldosterone** | **LOW** (distinguishes from hyperaldosteronism) | | **GFR** | Normal | **Key Distinguishing Features:** - **Hypertension + hypokalemia + metabolic alkalosis + LOW renin + LOW aldosterone** = Liddle syndrome - Contrast: Primary aldosteronism can also cause hypertension, hypokalemia, and alkalosis, but renin is suppressed while aldosterone is inappropriately elevated **Management:** - **Potassium-sparing diuretics:** Amiloride (0.3-0.6 mg/kg/day) or triamterene - Blocks overactive ENaC directly; very effective in Liddle - Raises serum K+ dramatically - **Avoid:** Potassium supplementation alone (ineffective; ENaC still causes excessive K+ wasting); NSAIDs; ACE inhibitors/ARBs (don’t address primary ENaC problem) - **Blood pressure control:** Amiloride usually sufficient; may need additional antihypertensive if BP not controlled - **Genetic counseling:** Autosomal dominant; 50% risk to offspring **Outcome:** - Excellent with amiloride therapy - Normal growth and development - Normal renal function - Blood pressure control achieved ------------------------------------------------------------------------ ## VI. PSEUDOHYPOALDOSTERONISM (PHA) **Classification:** **Type 1 (PHA1) - Autosomal Recessive Form (Systemic):** **Genetics:** - Gene: SCNN1B, SCNN1G (ENaC subunits; same genes as Liddle but recessive loss-of-function mutations) - Inheritance: Autosomal recessive **Pathophysiology:** - **Loss-of-function ENaC mutations** → collecting duct cannot reabsorb sodium adequately - → Salt-wasting (sodium cannot be reabsorbed; wasted in urine) - → **Hyperkalemia** (reduced positive charge gradient; K+ cannot be secreted) - → **Metabolic acidosis** (H+ cannot be secreted; K+ competes for secretion) - → **Elevated renin and aldosterone** (volume depletion stimulates RAAS; kidneys fail to respond despite high aldosterone) **Clinical Presentation:** - **Severe salt-wasting** (neonatal; failure to thrive) - Hyperkalemia (serum K+ 6-8 mEq/L) - Metabolic acidosis - Elevated BP in some cases (paradoxically; mechanism unclear; perhaps from renin-angiotensin effects) - Recurrent hyperkalemic episodes if sodium restricted **Laboratory Findings:** | Finding | Value | |----|----| | **Serum sodium** | Low to normal; hyponatremia possible | | **Serum potassium** | **HIGH** (6-8 mEq/L) | | **Serum HCO₃⁻** | \<20 mEq/L (metabolic acidosis) | | **Plasma renin** | **Elevated** (appropriate for salt-wasting) | | **Aldosterone** | **Elevated** (appropriate for hyperkalemia/acidosis) | | **Urinary sodium** | Elevated (sodium-wasting) | | **Urinary potassium** | Low (inability to excrete K+) | | **GFR** | Normal | **Key Distinguishing Features from Other Hyperkalemic States:** - **Aldosterone ELEVATED** (not suppressed as in Liddle syndrome) - Salt-wasting phenotype (not hypertension as in Liddle) - **Resistant to aldosterone:** High aldosterone but kidneys cannot respond (ENaC non-functional) **Management:** - **High sodium diet** (3-4 g sodium/day); may need parenteral sodium in severe neonatal cases - **Fluid resuscitation:** Address volume depletion - **Potassium restriction:** \<2 g/day - **Diuretics:** Loop diuretics (furosemide) for K+ wasting; **avoid potassium-sparing agents** (contraindicated) - **Potassium-lowering agents:** Sodium polystyrene sulfonate, patiromer (in acute severe hyperkalemia) - **Alkali:** Sodium bicarbonate (addresses acidosis; also Na+ supplementation) - **Avoid medications:** ACE inhibitors, ARBs, NSAIDs (increase hyperkalemia risk) **Prognosis:** - Excellent if salt intake maintained - Growth normal with adequate sodium - Renal function preserved (assuming no obstruction from hyperkalemia-induced effects) ------------------------------------------------------------------------ ## VII. NEPHRONOPHTHISIS AND CILIOPATHIES ### A. Nephronophthisis **Definition:** Progressive, bilaterally symmetric tubulointerstitial nephritis leading to renal insufficiency; most common genetic cause of ESRD in children (4-10% of pediatric ESRD). **Genetics:** - **Autosomal recessive inheritance** (most common) - Gene: NPHP genes (NPHP1-13; mutations encode proteins involved in ciliary structure/function) - Most common: NPHP1 (del chromosome 2q13, homozygous in 85% of Northern European cases) **Pathophysiology:** - **Defect in primary cilium** structure or function in renal tubular epithelial cells - Primary cilium: Sensory organelle; involved in fluid flow sensing, cell-cell signaling - Loss of ciliary function → abnormal cell signaling → tubulointerstitial inflammation - Characteristic histology: Corticomedullary cysts (medullary or inner cortical cysts); chronic tubule-interstitial fibrosis; glomeruli initially spared **Clinical Presentation:** **Early Childhood (Age 1-10 years, typically):** - Polyuria, polydipsia (earliest symptom; from distal tubule dysfunction) - Nocturnal enuresis (common) - Anemia (mild; from CKD) - Growth failure - Progressive renal insufficiency; serum creatinine rising **Progression:** - Progressive loss of renal function; GFR declining - Median age at ESRD: 13 years (range 5-20+; depends on genotype) - NPHP1 deletions: Earlier ESRD (median age 13); NPHP mutations: Slower progression (median age 20+) **Extrarenal Manifestations (Syndromic Forms):** - **NPHP1:** Pure nephronophthisis (no extrarenal features) — most common - **NPHP4 (Senior-Loken syndrome):** Nephronophthisis + ocular dystrophy (retinitis pigmentosa; progressive vision loss) - **NPHP8-10 (Joubert syndrome - related):** Nephronophthisis + cerebellar hypoplasia, developmental delay - **NPHP13:** Nephronophthisis + short-rib thoracic dysplasia - **Other ciliopathy associations:** Situs inversus totalis, heterotaxy, bronchiectasis, liver disease (congenital hepatic fibrosis) **Diagnosis:** **Clinical Suspicion:** - Polyuria + progressive renal insufficiency in child - Family history of ESRD in cousins/siblings (autosomal recessive) **Imaging:** - **Renal ultrasound:** Small, echogenic kidneys; characteristic cysts at corticomedullary junction (may not be obvious early) - **CT:** Corticomedullary cysts; helps confirm diagnosis - **MRI:** Excellent visualization of cysts; shows interstitial fibrosis **Histology:** - Kidney biopsy (if diagnosis uncertain): Tubulointerstitial fibrosis; corticomedullary cysts; relatively spared glomeruli - Electron microscopy: May show ciliary abnormalities (short, irregular cilia or complete absence) **Genetic Testing:** - NPHP1 homozygous deletion testing (covers 85% of cases) - Full NPHP gene panel (NPHP1-13) if deletion testing negative - **Ciliary function testing:** Immunohistochemistry for ciliary marker proteins **Management:** - **Supportive care:** ACEI/ARB (slow renal function decline; reduce proteinuria) - **CKD management:** Blood pressure control, anemia management, renal osteodystrophy prevention - **Renal replacement therapy:** Dialysis/transplantation when ESRD reached - **Genetic counseling:** Autosomal recessive; 25% risk to siblings - **Screening relatives:** Ultrasound for asymptomatic family members - **Syndromic assessment:** Ophthalmology (if Senior-Loken), neurology (if Joubert-related), cardiology (if situs anomalies) **Prognosis:** - Inevitable progression to ESRD (median 13-20 years depending on genotype) - Transplantation: Good outcomes; disease does not recur in transplanted kidney ------------------------------------------------------------------------ ### B. Ciliopathies Overview **Spectrum of Ciliary Disorders:** Ciliopathies involve dysfunction of primary cilium (found on most cell types, including renal tubular epithelium). **Renal Manifestations:** 1. **Nephronophthisis** (tubulointerstitial disease; progressive) 2. **Cystic kidney disease** (polycystic kidney, cystic dysplasia; linked to ciliary dysfunction in PKD genes) 3. **Glomerulonephritis** (rare; inverted architecture secondary to ciliary dysfunction) **Syndromic Ciliopathies with Renal Involvement:** | Syndrome | Key Features | Renal Manifestation | |----|----|----| | **Bardet-Biedl (BBS)** | Retinitis pigmentosa, polydactyly, obesity, cognitive delay | Cystic kidneys, CKD (30-40% develop ESRD) | | **Joubert Syndrome** | Cerebellar hypoplasia, developmental delay | Nephronophthisis if ciliopathy-related | | **Senior-Loken** | Nephronophthisis + retinitis pigmentosa | Progressive renal failure | | **Kearns-Sayre** | Mitochondrial disease; retinitis pigmentosa, cardiomyopathy | Variable renal involvement | | **Oral-Facial-Digital** | Cleft lip, digital abnormalities, developmental delay | Cystic kidneys (variable severity) | **Common Theme:** Ciliary dysfunction → abnormal epithelial signaling → abnormal tubule development, inflammation, and cyst formation ------------------------------------------------------------------------ ## VIII. CLINICAL PEARLS 1. **Bartter vs. Gitelman Key Differences:** Both present with hypokalemic metabolic alkalosis and normal BP, but Gitelman has **marked hypomagnesemia and LOW urinary calcium** (hypocalciuria), while Bartter types with hypercalciuria. 2. **NSAID Paradox:** NSAIDs worsen renal function overall but paradoxically improve Bartter/Gitelman by reducing renin-angiotensin-aldosterone activation; use with caution and monitor renal function. 3. **Type 1 RTA Nephrolithiasis Risk:** Contrary to expectations of “acidic urine prevents stones,” Type 1 RTA patients form **calcium phosphate stones** due to alkaluria (high urine pH) + hypercalciuria + hypocitraturia; aggressive alkali therapy critical. 4. **Cystinosis Diagnosis:** Photophobia + ocular cystine crystals (visible on slit-lamp) = **pathognomonic** for cystinosis; don’t miss by not asking about light sensitivity. 5. **Cysteamine Timing:** Earlier initiation (\